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ORIGINAL ARTICLE
Structural epicardial disease and microvascular
function are determinants of an abnormal
longitudinal myocardial blood flow difference
in cardiovascular risk individuals as determined
with PET/CT
Ines Valenta, MD,a Alessandra Quercioli, MD,a Gabriella Vincenti, MD,a
Rene´ Nkoulou, MD,a Stephan Dewarrat, MSc,b Olivier Rager, MD,b Habib Zaidi,
PhD,b Yann Seimbille, PhD,b Francois Mach, MD,a Osman Ratib, MD,b
and Thomas H. Schindler, MD, PhDa
Background. The aim of this study was to determine whether epicardial structural disease
may affect the manifestation of a longitudinal decrease in myocardial blood flow (MBF) or
MBF difference during hyperemia in cardiovascular risk individuals, and its dependency on the
flow increase.
Methods and Results. In 54 cardiovascular risk individuals (at risk) and in 26 healthy
controls, MBF was measured with 13N-ammonia and PET/CT in mL/g/min at rest and during
dipyridamole stimulation. Computed tomography coronary angiography (CTA) was performed
using a 64-slice CT of a PET/CT system. Absolute MBFs during dipyridamole stimulation were
mildly lower in the mid-distal than in the mid-LV myocardium in controls (2.20 ± .51 vs
2.29 ± .51, P < .0001), while it was more pronounced in at risk with normal and abnormal CTA
(1.56 ± .42 vs 1.91 ± .46 and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respectively, P < .0001),
resulting in a longitudinal MBF difference that was highest in at risk with normal CTA,
intermediate in at risk abnormal CTA, and lowest in controls (.35 ± .16 and .22 ± .09 vs
.09 ± .04 mL/g/min, respectively, P < .0001). On multivariate analysis, log-CCS and mid-LV
hyperemic MBF increase, indicative of microvascular function, were independent predictors of
the observed longitudinal MBF difference (P £ .004 by ANOVA).
Conclusions. Epicardial structural disease and microvascular function are important
determinants of an abnormal longitudinal MBF difference as determined with PET/CT. (J Nucl
Cardiol 2010;17:1023–33.)
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INTRODUCTION
Measurements of myocardial blood flow (MBF)
with PET at rest and its responses to sympathetic stim-
ulation with cold pressor testing or pharmacologically
stimulated coronary flow increases afford the non-
invasive identification and characterization of coronary
circulatory function in normal and diseased vascular
states.1-4 Hyperemic MBFs are considered to denote
predominantly endothelium-independent flow responses
owing to the relaxation of the vascular smooth muscle
cells of the arteriolar vessels during pharmacologic
vasodilation.1,2 Shear sensitive components of the
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coronary endothelium, however, contribute through
flow-mediated coronary vasodilation to the overall
hyperemic flow during pharmacologic vasodilation.1,2
As hyperemic MBFs during pharmacologic vasodilation
comprise up to 21-25% flow-mediated and, thus, endo-
thelium-related vasodilatory effects, it is also reported
as the ‘‘total integrated coronary circulatory func-
tion.’’1,2,5,6 Conversely, functional and/or structural
abnormalities of the coronary arterial wall may impair
flow-mediated coronary vasodilation predominantly of
the epicardial artery.7-10 Such functional alterations or
diffuse epicardial narrowing of the epicardial arter-
ies,7,9,11 commonly accompanied by an impairment of
flow-mediated vasodilation, have been suggested as
cause for a more recently described longitudinal
decrease in myocardial perfusion or MBF during phar-
macologically stimulated hyperemia.7-9 Until recently,
PET flow studies assessing the longitudinal base-to-apex
MBF gradient during pharmacologic vasodilation did
not provide information on the presence of structural
coronary artery disease (CAD). Thus, it remains uncer-
tain how the presence or absence of structural alterations
of the epicardial artery may affect the manifestation of
an abnormal longitudinal, base-to-apex MBF gradient
during higher coronary flows. Another aspect is that,
according to the Hagen–Poiseuille equation, the velocity
of coronary flow represents a major determinant of the
intracoronary resistance, apart from the fourth power of
the vessel diameter. According to this, a longitudinal,
base-to-apex MBF gradient during hyperemic flows,
most likely reflecting an impairment of a flow-mediated
coronary vasodilation and/or structural CAD, should be
more pronounced with higher flow increases as a con-
sequence of higher increases in intracoronary resistance
associated with a pressure drop along the epicardial
artery.12
With this in mind, we aimed to investigate whether
epicardial structural disease, as evidenced by CTA-
determined coronary morphology, may affect the man-
ifestation of a longitudinal decrease in MBF from the
mid to mid-distal segment of the left ventricle (LV) or
longitudinal MBF difference during hyperemic flows in
cardiovascular risk individuals, and its dependency on
the hyperemic flow increase.
MATERIALS AND METHODS
Study Population
The study population comprised 54 cardiovascular risk
individuals, who were referred for myocardial perfusion
imaging with 13N-ammonia and PET/CT (64-slice Biograph
HiRez TruePoint PET-CT scanner, Siemens Medical Solutions,
Erlangen, Germany) for the evaluation of flow-limiting CAD
(Table 1). In addition, 26 healthy controls without known
cardiovascular risk factors undergoing the same imaging pro-
tocol served as controls. In these individuals, coronary calcium
score (CCS) was determined and non-invasive computed
tomography coronary angiography (CTA) was performed with
64-slice CT of the PET/CT system. Only individuals with
normal stress–rest perfusion imaging, evaluated semiquantita-
tively on 13N-ammonia PET/CT, were included for study
purpose. The study population was grouped as follows: group 1,
healthy controls with normal CTA; group 2, cardiovascular risk
individuals with normal CTA; and group 3, cardiovascular
risk individuals but with evidence of both calcified and non-
calcified coronary plaque burden on CTA (abnormal CTA).
Individuals who presented only minor non-calcified plaque
burden were not included for study analysis. Cardiovascular
risk factors included the presence of arterial hypertension,
smoking, type 2 diabetes mellitus, hypercholesterolemia, or
family history of CAD. Patients with evidence of left ventric-
ular hypertrophy on the electrocardiogram were excluded from
study analysis. Vasoactive medications such as calcium channel
blockers, angiotensin-converting enzyme inhibitors, statin as
well as b-blockers, and diuretics were discontinued at least
24 hours before PET flow study during pharmacologic vaso-
dilation with dipyridamole and at rest. All study participants
refrained from caffeine-containing beverages for C24 hours
and from smoking for C12 hours prior to the PET study. The
study was approved by the University Hospitals of Geneva
Institutional Review Board (No. 07-184), and each participant
signed the approved informed consent form.
Calcium Scanning
Prior to PET flow studies, 64-slice multidetector com-
puted tomography (MDCT) of the Biograph HiRez TruePoint
PET-CT scanner (Siemens) determined coronary artery cal-
cium score (CCS). The scanner was operated in the single slice
mode with an image acquisition time of 100 ms and a section
thickness of 3 mm. Prospective ECG-triggering was done at
55% of the R–R interval. Contiguous slices to the apex of the
heart were obtained. CCS was considered present if three or
more contiguous pixels with a signal intensity of [130 HU
were identified.13 The size of the lesion was automatically
calculated, and the CCS was scored using the Agatston algo-
rithm.13 The CCS was computed across all lesions denoted
within the left main, left anterior descending artery (LAD), left
circumflex artery (LCx), and right coronary artery (RCA), and
the sum of all lesion scores yielded the total CCS.
PET Flow Studies
Following the topogram used to determine the axial
field of view and a low-dose CT scan (120 kV, 30 mA) for
attenuation correction, PET emission data were acquired
during shallow breathing. PET imaging during dipyridamole-
stimulated hyperemia (140 lg/kg/min) and at rest was com-
menced immediately following injection of approximately
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500-600 MBq of 13N-ammonia for a total duration of 18-min
list-mode PET data acquisition, respectively. The stress and
rest PET images were visually checked for accurate alignment
with the CT scan used for attenuation correction. In case of
misalignment between PET and CT images, CT data were
shifted in the horizontal and vertical directions in the transaxial
planes and in the superior-inferior direction of coronal planes
to visually align the heart borders visible on CT with the PET
emission data to achieve an accurate coregistration.14 The
reoriented 13N-ammonia images and the corresponding polar
maps were generated from the last 720-s image set and they
were also evaluated visually and semiquantitatively for stress
and rest regional perfusion abnormalities. The PET images
were assessed with a 17-segment model and a 5-point grading
system by two expert observers.15 Summed stress score (SSS),
summed rest score, and summed difference score (SDS) were
calculated.16 An SSS \4 was considered normal, 4-8 mildly
abnormal, 9-13 moderately abnormal, and [13 severely
abnormal perfusion. Further, an SDS C2 identified ischemia,
whereas\2 was considered a normal. Image interpretation was
visually performed in consensus by two nuclear cardiologists.
In the case of disagreement between observers, consent was
achieved in a joint reading.
Beginning with intravenous 13N-ammonia application,
serial transaxial emission images were recorded (12 images per
frame of 10 s each, 3 frames of 20 s each, and 6 frames of 30 s
each) with PET/CT, and time-activity curves from the first 12
dynamic frames (12 for 10 s each) in conjunction with a two-
compartment tracer kinetic model17 were used to calculate
regional and global MBF in mL/g/min. On the polar map of the
last 720-s image set, regions of interest (ROIs) were assigned
to the territories of the three coronary arteries using the
17-segment model.18 Applying the PMOD software package
(version 2.8 PMOD Technologies Ltd., Zurich, Switzerland),
MBF was determined in mL/g/min.19 The tracer kinetic model
applied, corrected for physical decay of 13N-ammonia, partial-
volume-related underestimations of true myocardial tissue
concentrations (by assuming a uniform myocardial wall
thickness of 1 cm),20,21 and spillover of radioactivity between
the left ventricular blood pool and myocardium.22 Regional
MBFs of the LAD, LCx, and RCA territory were averaged on a
polar map and the resulting mean MBF of the LV was defined
as global MBF. In addition, the assessment of longitudinal
flows, MBFs in the mid and mid-distal myocardial segment of
the LV corresponding to the vascular territories of the LAD
(segments: 7-8 and 13-14), LCx (segments: 11-12 and 16), and
RCA (segments: 9-10 and 15) were determined. Basal seg-
ments (LAD: 1-2, LCx: 5-6, and RCA: 3-4) and the apical
segment (LAD: 17), however, were not included for this
analysis owing to a possible count variability induced by the
membranous septum, by a certain variability in locating the
last apical slice, and by partial volume errors resulting from
object size at the apex.7 A decrease in MBF from mid to mid-
distal LV myocardium was defined as longitudinal MBF
Table 1. Clinical characteristics of the study population
Controls
At risk with
normal CTA
At risk with
abnormal CTA
Numbers (N) 26 26 28
Age (years) 38 ± 10 55 ± 12* 72 ± 10*
BMI (kg/m2) 23 ± 3 33 ± 11* 26 ± 5*
CCS (HU) 0 0 962 ± 933
Risk factors
Hypertension (N) 0 7 (27%) 7 (25%)
Smoking (N) 0 10 (38%) 13 (46%)
Hypercholesterolemia (N) 0 10 (38%) 17 (61%)
Obesity (N) 0 11 (42%) 4 (14%)
Family history of CAD (N) 0 7 (27%) 5 (18%)
Diabetes mellitus (N) 0 5 (19%) 8 (29%)
Fasting plasma concentrations
Cholesterol (mg/dL) 203 ± 33 208 ± 41 214 ± 45
LDL (mg/dL) 128 ± 38 136 ± 35 147 ± 30*
HDL (mg/dL) 54 ± 21 44 ± 12* 43 ± 11*
TG (mg/dL) 107 ± 78 130 ± 63 122 ± 39
Glucose (mg/dL) 92 ± 12 102 ± 13* 110 ± 21*
CRP (mg/dL) 1.8 ± 1.9 5.9 ± 9.2* 12.2 ± 15.8*
Numbers, N (%).
BMI, Body mass index; CCS, coronary artery calcium score; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG,
triglyceride; CRP, C-reactive protein.
*P B .05 vs controls and P B .05 vs at risk without CAC (t-test for independent samples).
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difference (mL/g/min) indicative of a perfusion gradient.
Changes in the longitudinal MBF difference from rest to
dipyridamol-stimulated hyperemia were defined as rest-
to-stress change in longitudinal MBF difference (D longitudinal
MBF difference = longitudinal MBF difference during hyper-
emia minus longitudinal MBF difference at rest). Heart rate,
blood pressure, and a 12-lead electrocardiogram were recorded
continuously during each MBF measurement. From the average
of heart rate and systolic blood pressure during the first 2 min of
each image acquisition, the rate-pressure product (RPP) was
derived as an index of cardiac work. To account for possible
interindividual variations in coronary driving pressure, an index
of global coronary vascular resistance (CVR) was determined
as the ratio of mean arterial blood pressure (mmHg) to MBF
(mL/g/min).
64-Slice MDCT Scanning Protocol
Following PET perfusion imaging, low-dose CTA using
the ECG-dependent dose modulation (‘‘ECG-pulsing’’) on a
dedicated 64-slice Biograph HiRez TruePoint PET-CT scanner
(Siemens) was performed in order to delineate coronary mor-
phology. Metoprolol was applied intravenously (5-40 mg)
(Lopressor, AstraZeneca) prior to CTA examination to achieve
the target heart rate of\65 bpm. Coaching and training of the
patient (practice of breath-hold) was performed before CT
scanning to avoid breathing artifacts. In addition, all patients
received isosorbide dinitrate 2.5 mg sublingual (Isoket spray,
Schwarz Pharma) to ascertain a maximal vasodilation of epi-
cardial artery. For CTA, 80 mL of iomeprol (Iomeron 400,
Bracco-Altana Pharma) was infused at a flow rate of 5 mL/s
followed by 50 mL saline solution into an antecubital vein via
an 18-gauge catheter. Bolus tracking was performed after the
injection of 20 mL of contrast agent (5 mL/s) by positioning
an ROI into the ascending aorta. CTA was performed with
retrospective gating, using the available tube current modula-
tion tool referred to as ‘‘ECG-pulsing.’’ Scanning parameters
were 64 9 .6 mm2 collimation, gantry rotation time 330 ms, a
pitch of .2, and pulse window 70% of the R–R cycle. Tube
voltage and tube current were adapted to the body mass index
(BMI) as described previously.23
CTA Image Interpretation
CTA images were analyzed visually and independently by
two experienced observers on axial source images, multiplanar
and curved reformations, and thin-slab maximum intensity
projections using the 2D/3D visualization software Vitrea 2
(Vital images, Inc.). Image quality for each data set was
evaluated on a five-scale score. Coronary arteries were ana-
lyzed according to a 15-segment model proposed by the
American Heart Association.24 Each segment was visually
analyzed on at least two planes, one parallel and one perpen-
dicular to the course of the vessel with regard to coronary
artery delineation, and all vessels with a diameter down to
1.5 mm were included in the analysis. The coronary artery
diameter in a non-branching vessel segment of the proximal
LAD, LCx, and RCA was evaluated in both longitudinal and
short axis views.24 The reported diameters of the proximal
coronary segments for each study participant resulted from the
average of both measurements. For each segment, both pres-
ence of atherosclerotic plaque and its composition were
determined. Atherosclerotic lesions were identified as mor-
phologically significant if the diameter stenosis was C50%.
Plaque lesions below this threshold were classified as mild and
non-significant lesions. Plaque composition was graded as non-
calcified plaque (plaques having lower density than contrast
enhanced lumen), calcified plaque (plaques with high density),
and mixed plaques (composition of both non-calcified and
calcified plaque burden).25
Statistics
Data are presented as the mean ± SD for quantitative and
absolute frequencies for qualitative variables. For comparison
of differences, appropriate t-tests for independent or paired
samples were used. Pearson’s correlation coefficient (r),
assuming a linear regression, was calculated to investigate
possible associations between MBF and CVR, hemodynamic
and cardiovascular risk parameters. Since CCSs followed a
skewed distribution, the CCSs were logarithmically trans-
formed (log-CCS) and related to the MBF and CVR data. In
addition, cardiovascular risk individuals with abnormal CTA
and CAC were also grouped according to tertiles of log-CCS
with \69.3 HU (lowest tertile), between 69.3 and 361.5 HU
(medium tertile), and[361.5 HU (highest tertile). Multivariate
analysis was performed with the logistic regression model.
Coronary non-calcified plaque burden and proximal artery
diameter were not entered into the multivariate model, because
they correlated with log-CCS.26 Statistical significance was
assumed if a null hypothesis could be rejected at P = .05. All
statistical analyses were performed with SPSS for Windows
17.0 (SPSS).
RESULTS
Clinical Characteristics
Table 1 summarizes the clinical characteristics of
the study population. In the cardiovascular risk group
with normal CTA, 9 patients had one coronary risk
factor, 12 patients had two, and 5 patients had three or
more coronary risk factors. As regards the cardiovas-
cular risk group with abnormal CTA, 7 patients had one
coronary risk factor, 16 patients had two, and 5 patients
had three coronary risk factors. In these cardiovascular
risk individuals, 20 patients had CAC in three-, 6 in
two-, and 2 in one coronary vessel with a mean CCS of
962 ± 933 HU (range 3.3-2678). A CCS \100, C100,
and[400 was present in 6 (21%), 5 (18%), and 6 (21%),
respectively. Eleven (39%) of these had a CCS [1000.
Due to the high coronary calcification burden, however,
87 out of 420 (21%) coronary segments were not
assessable for analysis of epicardial morphology. As far
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as coronary artery segments could be evaluated, mor-
phologically significant epicardial lesions (C50%
stenosis) could be identified in 7 (25%), whereas non-
calcified plaque burden was observed in 9 (33%), and
mixed plaques 25 (90%). Notably, in those seven car-
diovascular risk individuals where epicardial lesions
with C50% stenosis could be denoted by CTA, stress–
rest 13N-ammonia PET perfusion images were normal.
As regards the mean coronary artery diameter of the
proximal vessel segments of the LAD, LCx, and RCA
on CTA, it did not differ significantly between controls
and cardiovascular risk individuals with normal CTA
(3.90 ± .50 vs 3.83 ± .49 mm, P = .58), whereas it was
significantly higher in controls than in cardiovascular
risk individuals with abnormal CTA (3.90 ± .50 vs
3.60 ± .50 mm, P \ .03). Further, the mean proximal
artery diameter tended to be higher in cardiovascular
risk group with normal CTA than in the group with
abnormal CTA (3.83 ± .49 vs 3.60 ± .50 mm, P = .10).
The group comparison of the mean proximal artery
diameter in controls with normal CTA was not signifi-
cantly different from at risk groups with abnormal CTA
(P = .10 by ANOVA). Finally, in the cardiovascular
risk group with abnormal CTA, there was some corre-
lation between the mean proximal artery diameter and
log-CCS (r = -.33, SEE = .47; P \ .01).
Global MBF Measurements
and Hemodynamics
At rest, heart rate and systolic blood pressure and
corresponding RPP were higher in at risk groups than in
controls, whereas they were the highest in at risk with
abnormal CTA (Table 2). The latter was paralleled by a
progressive increase in resting MBF from controls to at
risk groups with normal and abnormal CTA. During
dipyridamole-stimulated hyperemia, heart rates had
increased significantly from rest but they were compa-
rable between groups (Table 2), whereas systolic blood
pressure had non-significantly decreased from rest. There
were no significant differences in heart rate or RPP during
pharmacologic vasodilation among the three study
groups, whereas global hyperemic MBFs were signifi-
cantly higher in controls than in at risk groups (Table 2).
Further, global hyperemic MBF was significantly lower
in at risk group with abnormal CTA than in those with
normal CTA. When the global hyperemic MBFs were
related to the mean arterial blood pressure in order to
account for possible interindividual variations in coro-
nary driving pressure, the resulting estimates of global
CVR (mean arterial blood pressure/MBF) mirrored the
MBF values at rest and during pharmacologic vasodila-
tion for each group studied. Thus, differences in coronary
Table 2. Myocardial flow parameters and hemodynamics during positron emission tomography
Controls
At risk with
normal CTA
At risk with
abnormal CTA
Flow parameters
Global MBF-rest .71 ± .13 .89 ± .21* .99 ± .22*
Global MBF-DP 2.29 ± .51 1.83 ± .49* 1.42 ± .38*
Global MFR 3.28 ± .70 2.14 ± .73* 1.45 ± .30*
Global CVR-rest 121 ± 23 104 ± 27* 91 ± 22*
Global CVR-DP 37 ± 9 50 ± 13* 60 ± 16*
Global DCVR -84 ± 20 -54 ± 27* -32 ± 17*
LMBF difference-rest .05 ± .03 .09 ± .09* .09 ± .06*
LMBF difference-DP .09 ± .04 .35 ± .16* .22 ± .09*
DLMBF difference .05 ± .05 .26 ± .14* .14 ± .10*
Hemodynamics
Rest-HR (bpm) 63 ± 6 67 ± 12 70 ± 11*
DP-HR (bpm) 87 ± 10 83 ± 12 79 ± 12*
Rest-SBP (mmHg) 115 ± 11 124 ± 22 125 ± 18*
DP-SBP (mmHg) 113 ± 10 122 ± 22 119 ± 18*
Rest-RPP 7233 ± 756 8259 ± 1892* 8839 ± 2140*
DP-RPP 9896 ± 1451 10067 ± 2051 9494 ± 2282
DRPP 2663 ± 1317 1807 ± 1784 656 ± 919*
MBF, Myocardial blood flow (mL/g/min); MFR, myocardial flow reserve; CVR, coronary vascular resistance (mmHg/mL/g/min);
LMBF, longitudinal MBF (mL/g/min); HR, heart rate; SBP, systolic blood pressure; RPP, rate-pressure product (HR 9 SBP).
*P B .05 vs controls and P B .05 vs at risk without CAC (t-test, independent samples).
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driving pressure during pharmacologic vasodilation can
be widely ruled out as cause for alterations in hyperemic
MBF responses. The group comparison of global hyper-
emic MBF and its corresponding CVR in controls was
significantly different from at risk groups (P \ .0001 by
ANOVA).
In at risk group with abnormal CTA and CAC, we
also evaluated a possible association between CAC
burden and global MBFs. In this regard, the log-CCS
was not related to global MBF at rest (r = .02,
SEE = .81; P = .91), whereas significant and inverse
associations between log-CCS and global hyperemic
flows (r = -.41, SEE = .74; P B .03) and MFR (r =
-.51, SEE = .70; P B .006) were noted. These obser-
vations were further substantiated, when global CVR
was related to log-CCS. Also here, global CVR at rest
was not correlated to log-CCS (r = .07, SEE = .81;
P = .72). In contrast, global CVR during hyperemia and
also the ratio of global CVR during hyperemia to CVR
at rest significantly correlated with log-CCS, respec-
tively (r = .47, SEE = .72; P B .012; and r = .51,
SEE = .69; P B .006).
Longitudinal MBF Differences
Resting MBFs were significantly lower in the mid-
distal than in the mid-LV myocardium in controls and in
at risk groups with normal CTA and with abnormal CTA
(.64 ± .13 vs .69 ± .13, .80 ± .22 vs 89 ± .24, and .91 ±
.20 vs 1.00 ± .23 mL/g/min, respectively, P \ .0001),
resulting in longitudinal MBF differences of which were
significantly higher in at risk groups than in controls
(Table 2) (Figure 1). As regards regional MBFs during
dipyridamole stimulation, they were significantly lower
in the mid-distal than in the mid-LV myocardium in
controls and in at risk groups with normal and abnormal
CTA (2.20 ± .51 vs 2.29 ± .51, 1.56 ± .42 vs 1.91 ±
.46, and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respec-
tively, P \ .0001), resulting in a longitudinal MBF
difference that was the highest in at risk group with
normal CTA, intermediate in at risk group with abnor-
mal CTA, and the lowest in controls (Table 2)
(Figure 1). In addition, the longitudinal MBF difference
during pharmacologic vasodilation was also signifi-
cantly higher in at risk group with normal CTA than
with abnormal CTA (P \ .0002). Similarly, the change
in longitudinal MBF difference from rest to hyperemia
defined as D longitudinal MBF difference (longitudinal
MBF difference during hyperemia minus longitudinal
MBF difference at rest) was significantly higher in at
risk groups with normal and abnormal CTA as compared
to controls (Table 2; Figure 2). Further, the D longitu-
dinal MBF difference was significantly higher in at risk
with normal CTA than in those with abnormal CTA. The
group comparison of the D longitudinal MBF differ-
ences in controls was significant compared to the at risk
groups (P \ .0001 by ANOVA).
When the longitudinal MBF difference was divided
into subgroups by the three major coronary vascular
territories (LAD, LCx, and RCA), no significant differ-
ence in longitudinal MBF difference between these
vascular territories for each group at rest and during
pharmacologically induced hyperemic flows was deno-
ted by ANOVA (Table 3). Further, to verify whether
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Figure 1. Longitudinal MBF difference in the three study
groups at rest and during pharmacologically induced
hyperemia.
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Figure 2. D longitudinal MBF difference (longitudinal MBF
difference during hyperemia minus longitudinal MBF differ-
ence at baseline) in the three study groups.
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CAC exerts downstream effects on coronary flows in at
risk group with abnormal CTA and CAC, the effects of
regional CAC on corresponding longitudinal MBF
difference were evaluated by tertile analysis. The lon-
gitudinal MBF difference at rest did not differ
significantly among the lowest, the medium, and the
highest tertile of log-CCS (.07 ± .08 vs .11 ± .09 vs
.08 ± .12 mL/g/min). Conversely, during pharmacolog-
ically induced hyperemic flows, the longitudinal MBF
difference was non-significantly higher in the lowest as
compared to the medium tertile of log-CCS (.25 ± .08 vs
.21 ± .11 mL/g/min), whereas it was significantly higher
than in the highest tertile of log-CCS (.25 ± .08 vs
.18 ± .11 mL/g/min) (Figure 3). Although the longitu-
dinal MBF difference during hyperemic flows was
higher in the medium than in the highest tertile of log-
CCS, it did not reach statistical significance (.21 ± .11
vs .18 ± .11 mL/g/min) (Figure 3). Thus, increases in
regional log CCS were accompanied by a significant and
progressive decrease in regional longitudinal MBF dif-
ference during pharmacologic vasodilation, while this
was not observed during rest. The regional log-CCS,
however, did not correlate with the corresponding
regional longitudinal MBF difference during hyperemic
flow stimulation, at rest, and with the D longitudinal
MBF difference, respectively (r = .12, SEE = .99;
P = .36, r = .15, SEE = .98; P = .25, and r = .22,
SEE = .97; P = .10). Finally, we also evaluated a pos-
sible association between the mean proximal artery
diameter and longitudinal MBF difference. Also here, no
association between the mean proximal artery diameter
and the corresponding regional longitudinal MBF dif-
ference during hyperemic flow stimulation and at rest,
respectively, in controls (r = .28, SEE = .04; P = .17
and r = .15, SEE = .21; P = .48), in cardiovascular risk
with normal CTA (r = .16, SEE = .18; P = .94 and
r = .08, SEE = .10; P = 0.70), and in cardiovascular
risk with abnormal CTA (r = .13, SEE = .09; P = .53
and r = .18, SEE = .11; P = .43) was observed.
Rest to Stress Change in Longitudinal MBF
Difference and Hyperemic Flows
As denoted in Figure 4A, the rest to stress D lon-
gitudinal MBF differences in at risk group with normal
and abnormal CTA correlated significantly with the
mid-LV MBF during pharmacologically induced
hyperemia (r = .62, SEE = .10; P \ .0001), implicat-
ing the increase in coronary blood flow as an
determinant of the D longitudinal MBF differences. This
finding was further emphasized when patients in at risk
groups with normal and abnormal CTA were analyzed
separately (Figure 4B, C). Also here, the D longitudinal
MBF difference in both at risk groups with normal
and abnormal CTA was significantly associated with
the mid-LV MBF during pharmacologic vasodilation,
respectively (r = .52, SEE = .12; P \ .007 and r =
Table 3. Regional longitudinal MBF differences
Longitudinal
MBF
difference
Controls At risk with normal CTA
At risk with abnormal
CTA
LAD LCx RCA LAD LCx RCA LAD LCx RCA
At rest .07 ± .06 .04 ± .03 .07 ± .04 .12 ± .12 .11 ± .13 .08 ± .10 .10 ± .08 .07 ± .09 .09 ± .09
During DP .10 ± .08 .11 ± .08 .09 ± .10 .33 ± .16 .30 ± .21 .38 ± .20 .23 ± .10 .20 ± .10 .22 ± .14
MBF, Myocardial blood flow (mL/g/min); DP, dipyridamole.
P = NS by ANOVA within groups.
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Figure 3. Comparison of longitudinal MBF difference during
pharmacologic vasodilation among cardiovascular risk indi-
viduals with abnormal CTA with the lowest (\69.3 HU), the
medium (69.3-361.5 HU), and the highest tertile ([361.5 HU)
of log-CCS.
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.52, SEE = .08; P \ .004), not observed in controls
(r = .07, SEE = .05; P = .73).
Determinants of D Longitudinal MBF
Differences
In the study group as a whole, on univariate anal-
ysis, BMI and hyperemic MBF in the mid-LV were
significantly associated with D longitudinal MBF dif-
ference (Table 4). In addition, we performed a
multivariate analysis to identify predictors of the D
longitudinal MBF difference, by which structural alter-
ations of the epicardial wall, as denoted by log-CCS, the
hyperemic MBF in the mid-LV, BMI, and smoking were
identified as independent predictors of D longitudinal
MBF difference. If only at risk groups with normal and
abnormal CTA were analyzed, then on univariate anal-
ysis log-CCS, hyperemic MBF in the mid-LV and age
were significantly associated with D longitudinal MBF
difference (Table 4). In addition, on multivariate anal-
ysis, hyperemic MBF in the mid-LV and triglyceride
levels proved to be independent predictors of D longi-
tudinal MBF difference.
DISCUSSION
The observations of this study provide first direct
evidence that epicardial structural disease and micro-
vascular function are important determinants of an
abnormal longitudinal MBF difference in cardiovascular
risk individuals, which is assumed to reflect an impair-
ment of a flow-mediated coronary vasodilation. Such
findings may agree with the Hagen–Poiseuille law,
which denotes the resistance to flow in a tube interacting
with serial branches along its length.27 According to
this, the intracoronary resistance depends on the coro-
nary flow velocity and inversely on the fourth power of
the vessel diameter, while interacting with branches
along its length, that causes flow shunting from the
parent artery and the longitudinal perfusion or MBF
gradient. As it was observed, the extent of the longitu-
dinal MBF difference was related to the severity of
CAC, which has been shown to reflect overall CAD
burden,26 and also to the increase in hyperemic MBF or
microvascular function. In cardiovascular risk individ-
uals with CAC, increases in CAC were paralleled by a
continuous decrease in the longitudinal MBF difference
during pharmacologic vasodilation. An explanation is
that with progressive proximal diffuse or segmental
narrowing of the proximal parent artery more than dis-
tally, proximal resistance at maximal flow may become
higher than distal artery resistance such that the gradual
longitudinal MBF gradient is reduced or eliminated,
again depending on the severity of proximal or distal
artery disease and extent of branch disease.7,9,10 Alter-
natively, more structural proximal disease may impair
downstream distal artery endothelial-mediated vasodi-
lation thereby also reducing the longitudinal MBF
gradient. Of further interest, the observed longitudinal
MBF difference during hyperemic flows in cardiovas-
cular risk individuals without evidence of epicardial
structural disease was more pronounced than in those
with structural CAD. In more advanced stages of CAD,
as denoted in this study by the presence and severity of
calcified and non-calcified coronary plaque burdens,
coronary arteriolar function may have already been
more severely altered than in those without normal
CTA. Advanced stages of microvascular disease in this
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Figure 4. Correlation between MBF mid-LV during dipyrid-
amole and D longitudinal MBF difference in all cardiovascular
risk individuals (A); and in those with normal CTA (B); and
with abnormal CTA (C).
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study population, associated with diminished hyperemic
flows, may in fact have offset the magnitude of the
longitudinal MBF gradient during pharmacologic vaso-
dilation, resulting in a less marked flow gradient than
one might have expected. This may also explain, at least
in part, that although increases in CAC were accompa-
nied by a continuous decrease in the longitudinal MBF
difference during pharmacologic vasodilation, individ-
ual measurements of CAC did not correlate with the
longitudinal MBF difference. It is equally possible that
the cardiovascular risk group with CAC was not large
enough or, conversely, that the range of longitudinal
MBF difference during hyperemic flows was not wide
enough to result in a statistically significant association.
However, as the intracoronary resistance relates to
the velocity of the blood flow, apart from the inverse
relation to the vessel diameter according to the Hagen–
Poiseuille law, higher increases in hyperemic MBFs in
cardiovascular risk individuals with normal CTA,
therefore, resulted in relatively higher and abnormal
elevations in intracoronary resistance due to an impair-
ment of a flow-mediated coronary vasodilation than in
those with abnormal CTA and lower hyperemic flows.
This is in line with the observed close correlation
between the hyperemic longitudinal MBF difference and
the MBF increase in the mid-LV during pharmacologic
vasodilation in cardiovascular risk individuals, identi-
fying the magnitude of hyperemic MBF increase as an
Table 4. Univariate and multivariate analysis
D Longitudinal MBF difference
Univariate analysis Multivariate analysis
PCC P-value Coefficient b (95% CI) P-value
Entire study group
Log-CCS .08 .469 -.394 (-.084 to .003) .034
MBF mid-LV (mL/g/min) .09 .450 .382 (.012–.169) .025
Age (years) .15 .194 .315 (.000–.005) .115
Sex (male/female) .13 .249 -.144 (-.112 to .032) .273
BMI (kg/m2) .30 .007 .271 (.000–.009) .055
SBP (mmHg) .07 .515 -.051 (-.003 to .002) .705
Total cholesterol (mg/dL) .10 .391 .064 (-.002 to .002) .845
LDL cholesterol (mg/dL) .13 .261 .182 (-.002 to .003) .544
HDL cholesterol (mg/dL) .09 .445 -.262 (-.005 to .001) .156
Triglycerides (mg/dL) .09 .438 -.186 (-.001 to .000) .174
Glucose (mg/dL) .17 .145 .181 (.000–.003) .177
CRP (mg/dL) .01 .970 .038 (-.003 to .004) .767
Smoking (pack/years) .05 .656 .325 (.001–.009) .028
Cardiovascular risk groups
Log-CCS .46 .0001 -.271 (-.067 to .014) .187
MBF mid-LV (mL/g/min) .62 .0001 .529 (.050–.242) .004
Age (years) .42 .001 -.192 (-.005 to .002) .312
Sex (male/female) .13 .346 -.045 (-.087 to .062) .739
BMI (kg/m2) .16 .242 -.032 (-.005 to .004) .839
SBP (mmHg) .08 .548 -.045 (-.002 to .002) .752
Total cholesterol (mg/dL) .11 .412 .015 (-.002 to .002) .959
LDL cholesterol (mg/dL) .08 .563 .372 (.000–.004) .183
HDL cholesterol (mg/dL) .18 .206 -.070 (-.005 to .003) .693
Triglycerides (mg/dL) .20 .145 -.359 (-.002 to .000) .021
Glucose (mg/dL) .05 .714 .144 (.000–.003) .292
CRP (mg/dL) .23 .137 -.025 (-.003 to .003) .853
Smoking (pack/years) .21 .132 .211 (-.001 to .006) .173
PCC, Pearson correlation coefficient; CCS, coronary artery calcium score;MBF, myocardial blood flow; BMI, body mass index; SBP,
systolic blood pressure; LDL cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, high-density lipoprotein cholesterol;
CRP, C-reactive protein.
P-values by ANOVA with significance level B0.05.
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important determinant of the abnormal longitudinal
MBF difference. Interestingly, a more recent investiga-
tion28 of stress and rest myocardial perfusion imaging
with 82rubidium PET in patients with subclinical CAD
described a regional decrease in resting myocardial
perfusion, while it was not observed during dipyridam-
ole-stimulated hyperemic flows. This mild longitudinal
decrease in resting myocardial perfusion was ascribed to
direct downstream effects of diffuse CAD, which
appeared to be overcome during hyperemic flow
stimulation. A previous invasive coronary angiographic
investigation by Schachinger and Zeiher29 may support
this consideration as increasing atherosclerotic wall
thickening, determined with intravascular ultrasound,
was associated with a decrease in baseline coronary
vasomotor tone. Similar observations were reported by
Tousoulis et al30 in that a flow-mediated epicardial
vasodilation during coronary flow-increases may not be
diminished only during vasomotor stress but also at
resting state in patients with structurally diseased coro-
nary arteries and reductions in the diameter of the
epicardial artery. Advanced regional structural and/or
functional alterations of the coronary circulation,
therefore, may possible lead to a relative and mild fall of
regional resting flow.28 These observations may also
accord with current findings where MBF quantification
demonstrated a mild longitudinal flow difference also at
resting condition. Yet, it has to be taken into account
for that partial volume effects during the data acquisition
in the apical portion of the LV are likely to have con-
tributed to lower apical MBFs and, thereby, to the
magnitude of the longitudinal MBF difference. While
the reason for these in part contrasting observa-
tions7,9,13,28,31 remains uncertain, it may be related to
differences in patients’ characteristics and/or differences
in the extent of CAD-related structural and functional
disease of the epicardial vascular wall.
LIMITATIONS
There are important limitations worthy to be con-
sidered in interpreting our data. First, in the cardio-
vascular risk group with diffuse and most commonly
moderate to severe CAC, the blooming artifacts of cal-
cified plaques on CTA did not allow a proper analysis in
a substantial number of coronary artery segments. Thus,
in this cardiovascular risk group, we cannot exclude that
more epicardial lesions with [50% diameter stenosis
were indeed present without being identified on CTA
due to CAC-induced blooming artifacts, which may
have affected coronary flows. On the other hand, normal
stress and rest myocardial perfusion on 13N-ammonia
PET/CT images, as inclusion criteria in the study pop-
ulation, widely argued against the presence of advanced
and flow-limiting of epicardial lesions. Further, left-
ventricular ejection fraction was normal at peak stress
and rest on gated PET, widely ruling out the presence of
hemodynamically significant epicardial lesions of the
left main stem or three vessels disease leading to diffuse
ischemia. Second, as we did not perform intravascular
coronary ultrasound in cardiovascular risk individuals
with normal CTA, early and subclinical CAD-related
structural alterations of the artery may have been present
as well, apart from coronary circulatory dysfunction, and
have also contributed to an impairment of flow-mediated
epicardial vasodilation with the manifestation of observed
hyperemic longitudinal MBF difference. Third, MBFs in
the mid and mid-distal left-ventricular segments were
measured and, thus, the longitudinal MBF difference
was determined over a relatively short longitudinal
distance in order to avoid confounding count variability
in the basal segments and partial volume effects in the
apical segment on MBF measurements.7 This in fact
may have led to an underestimation of the longitudinal
MBF difference during hyperemic flows when compared
to a different analysis approach as described by Gould
et al.7
CONCLUSIONS
In cardiovascular risk individuals with normal
stress–rest perfusion 13N-ammonia PET/CT perfusion
images, epicardial structural disease and microvascular
function are important determinants of an abnormal
longitudinal MBF difference, reflecting effects of early
coronary atherosclerosis without segmental flow-limit-
ing stenosis, but needing further clinical investigation.
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